The PGRS domain of Mycobacterium tuberculosis PE_PGRS Rv1759c antigen is an efficient subunit vaccine to prevent reactivation in a murine model of chronic tuberculosis.

A third of the world population is latently infected with Mycobacterium tuberculosis and many cases of active tuberculosis arise from latent bacilli reactivation. Thus, it is important to design new vaccines to prevent reactivation. Using an experimental model of chronic tuberculosis in B6D2F1 mice, we observed constant expression of Rv1759c antigen, a member of the PE_PGRS gene family, on the cell wall of phagocytosed mycobacteria by activated macrophages located in lung granulomas. This antigen induced production of IFN-gamma after stimulation of cell suspensions from mediastinal lymph nodes. It was notorius that chronic infected mice immunized with this antigen and treated with corticosterone to induce reactivation showed not change in colony forming units (CFU), compared with the significant bacilli increase in non-vaccinated mice treated with corticosterone. These results suggest that this antigen could play an important role in the immune response that maintains latent infection, and could therefore, be a good candidate as a new subunit vaccine to prevent disease reactivation.

[1]  A. Kochi,et al.  The global tuberculosis situation and the new control strategy of the World Health Organization. , 1991, Tubercle.

[2]  S. Laal,et al.  Antigens of Mycobacterium tuberculosis Expressed during Preclinical Tuberculosis: Serological Immunodominance of Proteins with Repetitive Amino Acid Sequences , 2001, Infection and Immunity.

[3]  I. Orme,et al.  Pulmonary Lymphatics Are Primary Sites of Mycobacterium tuberculosis Infection in Guinea Pigs Infected by Aerosol , 2006, Infection and Immunity.

[4]  D. Snider,et al.  The global threat of drug-resistant tuberculosis. , 1998, The New England journal of medicine.

[5]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[6]  J. Laclette,et al.  The PE-PGRS glycine-rich proteins of Mycobacterium tuberculosis: a new family of fibronectin-binding proteins? , 1999, Microbiology.

[7]  A. Kochi,et al.  Tuberculosis: a global overview of the situation today. , 1992, Bulletin of the World Health Organization.

[8]  P. Andersen,et al.  A novel TB vaccine; towards a strategy based on our understanding of BCG failure. , 2002, Vaccine.

[9]  G. Rook,et al.  Pathogenesis of tuberculosis in mice exposed tolow and high doses of an environmental mycobacterial saprophyte , 1997 .

[10]  Yu-Jin Jung,et al.  Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Flynn,et al.  The immunological aspects of latency in tuberculosis. , 2004, Clinical immunology.

[12]  P. Fine,et al.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. , 1996, Lancet.

[13]  N. Federspiel,et al.  Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. , 2000, Science.

[14]  J. Betts,et al.  Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.

[15]  Sayera Banu,et al.  Are the PE‐PGRS proteins of Mycobacterium tuberculosis variable surface antigens? , 2002, Molecular microbiology.

[16]  J. Flynn,et al.  Effects of aminoguanidine on latent murine tuberculosis. , 1998, Journal of immunology.

[17]  Gary K. Schoolnik,et al.  ideR, an Essential Gene in Mycobacterium tuberculosis: Role of IdeR in Iron-Dependent Gene Expression, Iron Metabolism, and Oxidative Stress Response , 2002, Infection and Immunity.

[18]  N. Maine,et al.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi , 1996, The Lancet.

[19]  B. Barrell,et al.  Massive gene decay in the leprosy bacillus , 2001, Nature.

[20]  G. Rook,et al.  Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection , 1997, Infection and immunity.

[21]  John Chan,et al.  Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. , 2003, The Lancet. Infectious diseases.

[22]  De Cock Km,et al.  Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. , 1999 .

[23]  G. Rook,et al.  Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis , 2002, Clinical and experimental immunology.

[24]  W. Bishai,et al.  Mechanisms of latency in Mycobacterium tuberculosis. , 1998, Trends in microbiology.

[25]  M. Brennan,et al.  Comparative Immune Response to PE and PE_PGRS Antigens of Mycobacterium tuberculosis , 2001, Infection and Immunity.

[26]  R. Appelberg,et al.  Failure of the Mycobacterium bovis BCG Vaccine: Some Species of Environmental Mycobacteria Block Multiplication of BCG and Induction of Protective Immunity to Tuberculosis , 2002, Infection and Immunity.

[27]  A. Cataldi,et al.  Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis. , 2006, Vaccine.